Thermo Fisher Scientific Inc (NYSE:TMO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Monday.
According to Zacks, “Thermo Fisher ended the year 2016 on a mixed note with adjusted earnings ahead of the Zacks Consensus Estimate and sales lagging the same. We remain encouraged by the company’s recent product launches along with strong emerging markets growth. In this regard, over the past three months, Thermo Fisher traded neck on neck with the Zacks categorized Medical Instruments industry. However, the company has started to outdo the broader industry on strong fourth-quarter bottom line performance and a solid outlook. We also look forward to Thermo Fisher’s acquisition of FEI Company which is going to boost its performance in life-science research. We also await the integration and expected synergy of Affimetrix. On the flip side, as expected, Thermo Fisher’s top-line performance in the quarter was affected by four less selling days resulting in flat organic growth. Competitive pressure and currency headwinds add further woes.”
TMO has been the topic of a number of other research reports. Leerink Swann reissued a “buy” rating and issued a $175.00 price target on shares of Thermo Fisher Scientific in a report on Sunday, November 20th. Jefferies Group LLC cut their price target on shares of Thermo Fisher Scientific from $163.00 to $160.00 and set a “hold” rating on the stock in a report on Monday, January 23rd. Goldman Sachs Group, Inc. (The) reissued a “conviction-buy” rating and issued a $168.00 price target (down previously from $170.00) on shares of Thermo Fisher Scientific in a report on Monday, December 12th. Evercore ISI raised their price target on shares of Thermo Fisher Scientific from $160.00 to $162.00 and gave the stock a “buy” rating in a report on Tuesday, January 31st. Finally, Deutsche Bank AG reissued a “buy” rating and issued a $163.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, January 18th. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Thermo Fisher Scientific currently has an average rating of “Buy” and a consensus price target of $169.71.
Thermo Fisher Scientific (NYSE:TMO) traded up 0.83% during midday trading on Monday, hitting $156.17. 789,647 shares of the stock were exchanged. Thermo Fisher Scientific has a 1-year low of $123.96 and a 1-year high of $160.68. The firm’s 50-day moving average price is $146.53 and its 200 day moving average price is $149.73. The firm has a market capitalization of $61.62 billion, a P/E ratio of 30.68 and a beta of 1.10.
Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Tuesday, January 31st. The company reported $2.41 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.03. The company had revenue of $4.95 billion for the quarter, compared to analysts’ expectations of $4.98 billion. Thermo Fisher Scientific had a net margin of 11.06% and a return on equity of 15.41%. The firm’s revenue was up 6.5% compared to the same quarter last year. During the same quarter last year, the company earned $2.12 EPS. Analysts expect that Thermo Fisher Scientific will post $9.16 earnings per share for the current fiscal year.
This news story was originally reported by sleekmoney and is the property of of sleekmoney. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this news story can be viewed at http://sleekmoney.com/thermo-fisher-scientific-inc-tmo-upgraded-by-zacks-investment-research-to-hold-2/1658453.html.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. American Research & Management Co. boosted its position in shares of Thermo Fisher Scientific by 540.0% in the third quarter. American Research & Management Co. now owns 640 shares of the company’s stock valued at $102,000 after buying an additional 540 shares during the period. Signaturefd LLC boosted its position in shares of Thermo Fisher Scientific by 10.6% in the second quarter. Signaturefd LLC now owns 842 shares of the company’s stock valued at $124,000 after buying an additional 81 shares during the period. First Command Bank purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at about $125,000. Penserra Capital Management LLC boosted its position in shares of Thermo Fisher Scientific by 100.0% in the third quarter. Penserra Capital Management LLC now owns 864 shares of the company’s stock valued at $137,000 after buying an additional 432 shares during the period. Finally, Cable Hill Partners LLC boosted its position in shares of Thermo Fisher Scientific by 27.1% in the third quarter. Cable Hill Partners LLC now owns 961 shares of the company’s stock valued at $152,000 after buying an additional 205 shares during the period. 87.80% of the stock is owned by institutional investors and hedge funds.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/thermo-fisher-scientific-inc-tmo-upgraded-by-zacks-investment-research-to-hold-2/1658453.html
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.